NASDAQ · Biotechnology

Cartesian Therapeutics, Inc. (RNAC) Stock

$8.09 +2.66% NASDAQ: RNAC Healthcare

Cartesian Therapeutics, Inc., a clinical-stage biotechnology company, provides mRNA cell therapies for the treatment of autoimmune diseases. The company’s lead product candidate is Descartes-08, an autologous mRNA chimeric antigen receptor T-cell cell therapy (CAR-T) directed against the B cell maturation antigen (BCMA), which is in Phase 2b clinical trials for the treatment of autoimmune diseases, generalized myasthenia gravis, and systemic lupus erythematosus, as well as rare pediatric disease designation for the treatment of juvenile dermatomyositis.

Valuation

MetricValue
Price$8.09
Market Cap$237.70M
P/E Ratio-1.36
P/B Ratio-1.43
P/S Ratio130.44
EPS (TTM)$-5.02
52-Week High$14.56
52-Week Low$5.60
Dividend Yield0.00%

Financials & Margins

MetricValue
ROE194.13%
ROA-52.63%
ROCE-33.52%
Gross Margin-2900.00%
Operating Margin-2900.00%
Net Margin-85.51%
Debt/Equity-0.08
Current Ratio8.60

Annual Financials (USD)

Metric20212022202320242025
Revenue$85.0M$111.0M$26.0M$39.0M$3.0M
Operating Profit$-5.0M$15.0M$-86.0M$-44.0M$-87.0M
Net Profit$-26.0M$35.0M$-220.0M$-77.0M$-130.0M
EPS$-6.60$3.00$-49.76$-3.29$-5.02
Op Margin-5.4%13.1%-332.3%-112.8%-3099.9%

Balance Sheet (USD)

Metric20212022202320242025
Total Assets$160.0M$166.0M$305.0M$435.0M$296.0M
Total Liabilities$137.0M$72.0M$745.0M$442.0M$423.0M
Cash$114.0M$106.0M$77.0M$213.0M$125.0M
Borrowings$35.0M$38.0M$11.0M$14.0M$13.0M

Latest News

Kyverna Therapeutics Sinks 13%: Here’s Why 24/7 Wall St. · Jul 10, 2026 Cartesian Therapeutics Announces New Employment Inducement Grants GlobeNewswire · Jul 2, 2026 New Strong Sell Stocks for July 1st Zacks · Jul 1, 2026 Kiniksa Pharmaceuticals International, plc (KNSA) Surges 5.4%: Is This an Indication of Further Gains? Zacks · Jun 30, 2026 Cartesian Therapeutics Announces New Employment Inducement Grant GlobeNewswire · Jun 12, 2026

Cash Flow (USD)

Metric20212022202320242025
Operating Cash Flow$-60.0M$-32.0M$-51.0M$-24.0M$-74.0M
Investing Cash Flow$-18.0M$-16.0M$34.0M$-18.0M$-11.0M
Financing Cash Flow$1.0M$0$-6.0M$4.0M$-8.0M
Net Cash Flow$-25.0M$-7.0M$-30.0M$136.0M$-87.0M
Free Cash Flow$-61.0M$-33.0M$-51.0M$-33.0M$-79.0M

Valuation & Return Ratios

MetricValue
PEG Ratio0.01
EV / EBITDA-0.77
FCF Yield-33.24%
Quick Ratio8.60
Interest Coverage0.00
Return 1Y-40.85%
Return 3Y-76.64%
Return 5Y-92.04%

Ownership

Insiders Held53.68%
Institutions Held25.20%
Institutions Float Held54.41%
Institutional HolderSharesReport Date
Squarepoint Ops LLC2,238,4862026-03-31
FMR, LLC799,7432026-03-31
Blackrock Inc.599,1082026-03-31
Vanguard Capital Management LLC407,5972026-03-31
683 Capital Management LLC330,0002026-03-31

Peer Comparison

TickerPriceChangeP/EMarket CapDiv Yield
AARD $6.42 -4.04% -1.62 $140.50M 0.00%
AVTX $18.97 +2.87% -2.79 $214.25M 0.00%
EPRX $6.05 +4.13% -5.99 $202.55M 0.00%
FENC $10.21 +2.20% -27.42 $354.67M 0.00%
GNFTGenfit S.A. $8.95 +4.07% 261.07 $445.68M 0.00%

About Cartesian Therapeutics, Inc.

Cartesian Therapeutics, Inc., a clinical-stage biotechnology company, provides mRNA cell therapies for the treatment of autoimmune diseases. The company’s lead product candidate is Descartes-08, an autologous mRNA chimeric antigen receptor T-cell cell therapy (CAR-T) directed against the B cell maturation antigen (BCMA), which is in Phase 2b clinical trials for the treatment of autoimmune diseases, generalized myasthenia gravis, and systemic lupus erythematosus, as well as rare pediatric disease designation for the treatment of juvenile dermatomyositis. It is also developing Descartes-15, which is in phase 1 trials, an autologous autologous B cell maturation antigen (BCMA) directed mRNA CAR-T to treat patients with multiple myeloma. The company is headquartered in Frederick, Maryland.

Cartesian Therapeutics, Inc. is led by CEO Carsten Brunn, publicly traded since 2016.

Cartesian Therapeutics, Inc. (RNAC) stock trades at $8.09 with a market capitalization of $237.70M. The stock is valued at a price-to-earnings (P/E) ratio of -1.36, price-to-book of -1.43, price-to-sales of 130.44. Over the past 52 weeks the stock has ranged between $5.60 and $14.56, and currently trades 44.4% below its 52-week high.

On profitability, Cartesian Therapeutics, Inc. generates a return on equity (ROE) of 194.13% — well above the market average, a sign of a high-quality business, return on capital employed of -33.52%, an operating margin of -2900.00%, a net profit margin of -85.51%.

Official website: cartesiantherapeutics.com

Related Healthcare Stocks

LLY Drug Manufacturers - General $1185.71 -0.52% JNJ Drug Manufacturers - General $259.24 +0.88% ABBV Drug Manufacturers - General $246.04 +0.89% UNH Medical - Healthcare Plans $407.08 +0.77% MRK Drug Manufacturers - General $128.57 +0.16% NVS Drug Manufacturers - General $158.83 -0.64% NVO Biotechnology $51.58 +1.22% TMO Medical - Diagnostics & Research $594.00 +2.41% AMGN Drug Manufacturers - General $387.64 -1.39% ABT Medical - Devices $108.03 +0.70% GILD Drug Manufacturers - General $132.73 -1.18% PFE Drug Manufacturers - General $26.74 +2.06%

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)JPMorgan (JPM)Visa (V)

Screens featuring this stock

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksNasdaq High ROE StocksAll stock screens
Run Stock Screener Investing Guides